South San Francisco, California, October 4th, 2024 – Synlico Inc., an AI-based drug design company focusing on revolutionizing medicine by leveraging causality to make cellular processes explainable, predictable, and engineerable, is thrilled to announce it has been selected as a finalist in Johnson & Johnson Innovation’s QuickFire Challenge: Pitching AI for Pharmaceutical R&D.
The Pitching AI for Pharmaceutical R&D QuickFire Challenge is an opportunity for innovators to share strategies and approaches to harness AI to accelerate or automate pharmaceutical R&D for the chance to showcase their proposals to Johnson & Johnson’s Innovative Medicine R&D Data Science & Digital Health leadership team.
As a finalist, Synlico was invited to present its CausalCell AI platform to a panel of experts at the West Coast Summit hosted by Johnson & Johnson and California Life Sciences. The West Coast Summit brought together expert perspectives from the pharmaceutical industry, the startup world, and the investor community – focused on how AI is driving the discovery, development and delivery of innovative medicines today, and what the future holds in this rapidly-evolving space.
“We are honored to be named a finalist in such a highly competitive field,” said Dr. Jingwei Lu, Founder and Chief Executive Officer of Synlico Inc. “Our innovative team is dedicated to developing the cutting-edge CausalCell AI platform that aims to transform biology by decoding causality in engineering cells.”
Inspired by the limitations of correlation-based methods, Synlico focuses on a causal-based architecture to transform biological research and drug discovery by focusing on establishing causal links and strong predictive power regarding how modulating cells alters their behavior within patients’ microenvironments. Synlico is addressing three key healthcare challenges: low drug potency due to disease microenvironment heterogeneity, discrepancy from preclinical results to clinical efficacy, and inefficient screening-based drug design approaches.
Synlico Inc. is a resident company of Johnson & Johnson Innovation – JJDC, Inc. (JLABS), a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world.
About Synlico Inc.
Synlico is at the forefront of transforming biology by leveraging causality to make cellular processes explainable, predictable, and engineerable. Synlico’s focus is on developing innovative therapies for oncology and other diseases by employing the latest developments in machine learning & deep learning, causal discovery & inference, and single-cell bioinformatics. Synlico’s unique causality- and prediction- focused approach lies in predicting how cell modulation alters its behavior in patients’ microenvironment to navigate the complexities/heterogeneity of diseases. Visit www.synlico.com to find out more.
Synlico Inc. contacts:
Linda Guo
